Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study.
Camila PeñaEloisa RivaNatalia SchutzLuz Tarín-ArzagaHumberto Martínez-CorderoVirginia BoveRocío OsorioMauricio ChandíaCecilia BeltránJavier SchulzDaniela CardemilCarolina ContrerasCarmen Gloria VergaraJaviera DonosoMarcela EspinozaGabriel La RoccaHernán López-VidalPilar LeónChristine Rojas HopkinsPablo SotoSandra ArandaVivianne TorresMacarena RoaPaola OchoaPatricio Jose DuarteGuillermina RemaggiSebastián YantornoAriel CorzoSoledad ZabaljaureguiClaudia ShanleySergio LoprestiSergio OrlandoVerónica VerriLuis QuirogaCarlos GarcíaVanesa FernándezJhoanna RamirezAlicia MolinaMaría PachecoAlex MiteInés ReyesBrenner SabandoFrancisca RamírezClaudia SossaVirginia AbelloHenry IdroboKenny Mauricio Galvez CardenasDomingo SaavedraGuillermo QuinteroRaimundo GazitúaLina GaviriaRigoberto GomezMónica OsunaAlicia Henao-UribeOmar Cantú-MartínezGuillermo José Ruiz ArgüellesYarely Itzayana García-NavarreteAntonio Cruz-MoraYahveth Cantero-FortizGuillermo José Ruiz-ArguellesDorotea FantlPublished in: Leukemia & lymphoma (2020)
The aim of this study was to describe clinical and survival characteristics of transplant-eligible multiple myeloma (MM) patients in Latin America (LA), with a special focus on differences between public and private healthcare facilities. We included 1293 patients diagnosed between 2010 and 2018. A great disparity in outcomes and survival between both groups was observed. Late diagnosis and low access to adequate frontline therapy and ASCT in public institutions probably explain these differences. Patients treated with novel drug induction protocols, followed by autologous stem cell transplantation (ASCT) and maintenance, have similar overall survival compared to that published internationally.
Keyphrases
- newly diagnosed
- healthcare
- end stage renal disease
- stem cell transplantation
- chronic kidney disease
- ejection fraction
- multiple myeloma
- prognostic factors
- mental health
- randomized controlled trial
- emergency department
- patient reported outcomes
- stem cells
- metabolic syndrome
- skeletal muscle
- bone marrow
- weight loss
- adverse drug
- electronic health record
- drug induced